Skip to content

Author

Nicholas C. Gervais

We have 2 of 20 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

CRISPR-activation reveals key resistance genes and vulnerabilities of copy number variants in Candida albicans

Additive fitness effects of individual gene overexpression are a significant predictor of the fitness of multiple isolates with CNVs and can explain fitness trade-offs observed between classes of antifungal drug for the CNV isolates.

Pétra L. Vande Zande, Nicholas C. Gervais, Erika Schell et al. · 0 citations
Open access Jul 2026

Chromosome-scale CRISPR screening reveals secretory pathway genes as drivers of aneuploidy-mediated antifungal tolerance

This work functionally dissects one of the most common aneuploidies observed in C. albicans, provides mechanistic insight into the molecular basis of antifungal tolerance, and establishes a generalizable framework for studying aneuploidy-mediated phenotypes across eukaryotic organisms.

Nicholas C. Gervais, Lauren F. Wensing, Manini Chhina et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.